deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 12-arm NCT03215030

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma (iinnovate-1)

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma

Sponsor: Teva Branded Pharmaceutical Products R&D LLC

Conditions Multiple Myeloma
Interventions Dexamethasone Modakafusp alfa
Updated 37 times since 2017 Last updated: Jan 12, 2026 Started: Oct 4, 2017 Primary completion: Jul 1, 2024 Completion: Nov 7, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated by the sponsor for strategic reasons

Other terminated trials from Teva Branded Pharmaceutical Products R&D LLC

More terminations from Teva Branded Pharmaceutical Products R&D LLC

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

Listed as NCT03215030, this PHASE1/PHASE2 trial focuses on Multiple Myeloma and remains terminated or withdrawn. Sponsored by Teva Branded Pharmaceutical Products R&D LLC, it has been updated 37 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Jan 2019 · 4 months · monthly snapshot~Jan 2019 – ~Nov 2019 · 10 months · monthly snapshot~Nov 2019 – ~Jun 2020 · 7 months · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshot~Nov 2021 – ~May 2022 · 6 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Mar 2023 · 59 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Jun 2024 · 5 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Jan 2026 · 2 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

37 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jan 2026 — Feb 2026 [monthly]

    Terminated PHASE1/PHASE2

  3. Nov 2025 — Jan 2026 [monthly]

    Terminated PHASE1/PHASE2

    Status: Completed → Terminated

  4. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE1/PHASE2

  5. Jan 2025 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 32 earlier versions

  1. Nov 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

  7. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  11. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  12. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  13. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jan 2023 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  15. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  16. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  17. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  18. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  19. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  20. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE1_PHASE2

  21. Nov 2021 — May 2022 [monthly]

    Recruiting PHASE1_PHASE2

  22. Jan 2021 — Nov 2021 [monthly]

    Recruiting PHASE1_PHASE2

  23. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Active Not Recruiting → Recruiting

  24. Jun 2020 — Jul 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  25. Nov 2019 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  26. Jan 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  27. Sep 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  28. Jul 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  29. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  30. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  31. Sep 2017 — Nov 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  32. Aug 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Teva Branded Pharmaceutical Products R&D LLC
Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alessandria, Italy , Ancona, Italy , Argenteuil, France , Athens, Greece , Atlanta, United States , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Beijing, China , Birmingham, United Kingdom and 74 more locations